About Forge Biologics
Forge Biologics is a company based in Columbus (United States) founded in 2020 by Jaysson Eicholtz and Timothy Miller was acquired by Ajinomoto in November 2023. Forge Biologics has raised $250 million across 4 funding rounds from investors including Ajinomoto, Marshall Wace and Citadel. Forge Biologics offers products and services including AAV Manufacturing Solutions, Plasmid DNA, and FUEL Platform. Forge Biologics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Columbus, United States
- Founders Jaysson Eicholtz, Timothy Miller
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Forge Biologics
Forge Biologics offers a comprehensive portfolio of products and services, including AAV Manufacturing Solutions, Plasmid DNA, and FUEL Platform.
Provides end-to-end manufacturing for AAV therapies in development stages.
Offers plasmid DNA for gene therapy applications and research.
Supports gene therapy programs with integrated manufacturing tools.
People of Forge Biologics
Unlock access to complete
Unlock access to complete
Funding Insights of Forge Biologics
Forge Biologics has successfully raised a total of $250M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $90 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Forge Biologics
Forge Biologics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Ajinomoto, Marshall Wace and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on pre-seed and seed stage investments
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Private debt funds are managed across multiple sectors.
|
Locked | Locked | Locked |
Investor details for Forge Biologics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Forge Biologics
Investment portfolio details for Forge Biologics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Forge Biologics
Detailed financials for Forge Biologics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Forge Biologics Comparisons
Peer comparison for Forge Biologics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Forge Biologics
Forge Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
Detailed competitors of Forge Biologics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Forge Biologics
Complete news archive for Forge Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Forge Biologics
Forge Biologics was founded in 2020.
Forge Biologics is headquartered in Columbus, United States. It is registered at Columbus, Ohio, United States.
Timothy Miller is the current CEO of Forge Biologics. They have also founded this company.
Forge Biologics is a funded company, having raised a total of $250M across 4 funding rounds to date.
Forge Biologics was founded in 2020 and is headquartered in Columbus, United States. Gene therapeutic solutions are developed by the company within the biotechnology sector, targeting rare and monogenic diseases as well as certain cancers. Specific products include FBX-101, which addresses infantile Krabbe disease; FBX-201, aimed at rare monogenic conditions; and FBX-301, focused on rare diseases and oncology applications. Operations emphasize the advancement of these therapies for clinical use.
Forge Biologics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Forge Biologics offers AAV Manufacturing Solutions, Plasmid DNA, and FUEL Platform.
Forge Biologics has 10 investors. Key investors include Ajinomoto, Marshall Wace, Citadel, RA Capital, and MidCap Financial.